Supplemental Materials

Table S1: List of Psychiatric Disc	orders and the Corresponding ICD-9-CM Codes
Conditions	ICD-9-CM codes
Psychotic disorders	290.00-295.99, 296.24, 296.34, 297.00-298.09, 298.30-299.99 [except 299.00-299.19 and 299.80-299.89], and 310.00-310.99
Disruptive behavior disorders	309.30- 309.39, 312.00-312.49, 312.80-312.99, 313.81, and 314-314.99
Mood disorders	296.82, 301.12, 313.10-313.19, 296.2-296.23, 296.25-296.33, 296.34-296.39, 296.90-296.99, 300.40-300.49, 301.10-301.19, 311.00- 311.99, 296.00-296.19, 296.4-296.81, 296.89, 301.11, and 301.13
Tic disorders	307.20-307.29
Pervasive developmental disorders or mental retardation	299.00-299.19, 299.80-299.89, and 317.00-319.99
Other mental disorders	300.00-300.09, 300.20-300.39, 300.90-300.99, 307.00-307.99 [except 307.20-307.29], 308.00-308.99, 309.21, 309.81, 313.00-313.09, 313.20-313.29, and 315.00-315.99

Table S2 : C	C					vents using time varying antipsychotic exposure and lag exposure effectiveness.							ffects		
3	30 days lag	geffect	(Main												
	ana	alysis)		No l	ag effec	et	7 days	lag effec	et	60 days	lag effe	ect	Liberal	definiti	on*
Parameter	AHR	95%	CI	AHR	95%	CI	AHR	95%	CI	AHR	95%	CI	AHR	95%	CI
		I	ωw		Low	High		Low	High		Low	High		Low	High
		Hig	h												
Exposure (Ref: No	exposure) [©]	20													
Monotherapy	1.22	0.87	1.73	1.29	0.94	1.79	1.34	0.96	1.86	1.10	0.76	1.58			
Polypharmacy	1.72	0.73	4.04	2.34	0.85	6.47	1.92	0.69	5.30	1.28	0.57	2.89	1.06	0.62	1.83
Age group (Ref: 16-	-17 years)														
1-6 years	0.39	0.17	0.90	0.39	0.17	0.90	0.39	0.17	0.89	0.40	0.17	0.92	0.40	0.18	0.93
7-12 years	0.63	0.42	0.97	0.63	0.41	0.96	0.63	0.41	0.96	0.64	0.42	0.98	0.65	0.43	0.99
13-15 years	1.05	0.73	1.52	1.05	0.73	1.52	1.05	0.73	1.51	1.06	0.73	1.53	1.06	0.74	1.54
Gender (Ref: Male))														
Female	1.11	0.81	1.52	1.11	0.81	1.53	1.11	0.81	1.53	1.10	0.80	1.52	1.10	0.80	1.51
Region (Ref: Mid-w	vest)														
East	1.28	0.88	1.86	1.27	0.87	1.86	1.27	0.87	1.86	1.28	0.88	1.86	1.28	0.88	1.86
South	0.88	0.58	1.34	0.89	0.58	1.35	0.89	0.58	1.35	0.88	0.58	1.34	0.88	0.57	1.33
West	0.55	0.31	0.97	0.55	0.31	0.97	0.55	0.31	0.97	0.55	0.31	0.96	0.55	0.31	0.96
Index year	1.05	0.97	1.14	1.05	0.97	1.14	1.05	0.97	1.14	1.05	0.97	1.14	1.05	0.97	1.14
Common Antipsych	notic Provi	der (Re	f: Pedia	trician)											
Others	1.93	0.83	4.50	1.93	0.83	4.51	1.93	0.83	4.50	1.95	0.84	4.54	1.96	0.84	4.56
Psychiatrist	1.67	0.71	3.93	1.67	0.71	3.91	1.66	0.71	3.91	1.69	0.72	3.98	1.71	0.73	4.01
General Practice/	1.42	0.49	4.15	1.43	0.49	4.16	1.43	0.49	4.15	1.42	0.49	4.15	1.42	0.49	4.15
Family Practice															
Psychologist	0.77	0.23	2.53	0.77	0.23	2.53	0.76	0.23	2.53	0.77	0.23	2.55	0.78	0.24	2.56
Missing	1.17	0.48	2.80	1.16	0.48	2.80	1.17	0.48	2.81	1.17	0.48	2.80	1.16	0.48	2.80
Any Psychiatric rela	ated hospi	talizatio	n												
Yes	0.87	0.57	1.31	0.87	0.58	1.32	0.87	0.58	1.32	0.87	0.57	1.31	0.86	0.57	1.31

Mental Health (Ref: N	(o)														
Psychotic disorder	1.32	0.71	2.48	1.32	0.71	2.47	1.32	0.70	2.47	1.33	0.71	2.50	1.34	0.72	
ADHD	0.93	0.57	1.54	0.93	0.57	1.54	0.93	0.56	1.54	0.94	0.57	1.55	0.94	0.57	1.56
medications or															
Disruptive															
behavior disorder															
Antidepressants or	1.17	0.71	1.95	1.17	0.70	1.94	1.17	0.71	1.95	1.17	0.71	1.95	1.17	0.71	1.95
Mood disorder															
Antianxiety or	1.28	0.65	2.53	1.29	0.65	2.53	1.29	0.66	2.54	1.27	0.64	2.50	1.26	0.64	2.47
Sedative/hypnotic															
Other mental	0.91	0.54	1.53	0.90	0.54	1.52	0.90	0.54	1.52	0.91	0.54	1.53	0.91	0.54	1.54
disorder (including															
tic disorder)															
Pervasive	1.14	0.59	2.21	1.13	0.58	2.19	1.13	0.58	2.18	1.16	0.60	2.24	1.17	0.60	2.25
developmental															
disorder															4 40
Mood stabilizers	1.01	0.65	1.59	1.01	0.64	1.58	1.01	0.65	1.59	1.02	0.65	1.60	1.02	0.65	1.60
No. of different catego	ries of p	osychot	ropic me	dication	s taken ((Ref: 0)									
1	0.88	0.58	1.33	0.87	0.57	1.33	0.87	0.57	1.33	0.88	0.58	1.34	0.88	0.58	1.34
>=2	0.92	0.50	1.71	0.92	0.50	1.70	0.91	0.49	1.69	0.93	0.50	1.73	0.94	0.51	1.74
No. of different catego	ries of p	osychiat	tric disoı	ders dia	gnosed	(Ref: 0)									
1	1.17	0.69	1.99	1.17	0.69	1.99	1.17	0.69	1.99	1.17	0.69	1.98	1.17	0.69	1.98
2	1.00	0.47	2.14	1.00	0.47	2.14	1.00	0.47	2.14	1.00	0.47	2.13	0.99	0.46	2.12
3	1.33	0.45	3.93	1.33	0.45	3.92	1.33	0.45	3.92	1.32	0.45	3.90	1.31	0.45	3.88
>=4	1.12	0.22	5.55	1.12	0.23	5.59	1.13	0.23	5.60	1.09	0.22	5.43	1.07	0.22	5.35
Charlson comorbidity	score (Ref: 0)													
1	1.35	0.86	2.13	1.35	0.86	2.13	1.35	0.86	2.13	1.34	0.85	2.11	1.33	0.85	2.10
>=2	2.74	1.00	7.54	2.72	0.99	7.49	2.72	0.99	7.49	2.79	1.01	7.68	2.81	1.02	7.75
Intragroup Comparison [#]	Pr>	ChiSq		Pr	> ChiSq		Pr>	ChiSq		Pr >	ChiSq				

Monotherapy vs	0.4180	0.2469	0.4826	0.6880	
Polypharmacy					

AHR=Adjusted Hazard Ratio

^{*} For the liberal definition, time before polypharmacy initiation was considered as monotherapy time and time afterwards was considered as polypharmacy time; @- For this analysis, monotherapy was used as the reference group. #- Wald test for equal coefficients

Table S3: Sensitivity analysis results of Cox regression results for Metabolic adverse events using time varying antipsychotic exposure and lag exposure effects by excluding patients with less than 14 days of overlap use 30 days lag effect No lag effect 7 days lag effect 60 days lag effect Liberal definition* Parameter 95% CI AHR 95% CI 95% CI 95% CI **AHR** 95% CI AHR AHR AHR High High High High Low Low Low Low Low High Exposure (Ref: No exposure)@ Monotherapy 1.19 0.84 1.69 1.28 0.92 1.78 1.30 0.93 1.81 1.07 0.74 1.56 Polypharmacy 1.14 0.35 3.68 2.04 0.64 6.54 1.74 0.54 5.59 0.78 0.24 2.53 1.02 0.51 2.02 Age group (Ref: 16-17 years) 1-6 years 0.44 0.19 1.01 0.43 0.19 1.00 0.43 0.19 0.99 0.44 0.19 1.02 0.44 0.19 1.03 1.05 0.45 1.08 7-12 years 0.69 0.45 1.07 0.68 0.44 1.06 0.68 0.44 0.70 0.70 0.46 1.09 13-15 years 1.12 0.76 1.64 1.12 0.76 1.63 1.11 0.76 1.63 1.12 0.77 1.65 1.13 0.77 1.65 Gender (Ref: Male) Female 1.13 0.82 1.57 1.14 0.82 1.58 1.14 0.82 1.58 1.13 0.81 1.57 1.13 0.81 1.56 **Region (Ref: Mid-west)** East 1.19 0.81 1.77 1.19 0.80 1.77 1.19 0.80 1.77 1.20 0.81 1.78 1.20 0.81 1.78 South 0.90 0.59 1.38 0.90 0.59 1.38 0.90 0.59 1.38 0.90 0.59 1.37 0.90 0.59 1.37 0.94 West 0.52 0.29 0.93 0.52 0.29 0.52 0.29 0.94 0.52 0.29 0.93 0.52 0.29 0.93 Index year 1.04 0.96 1.13 1.04 0.96 1.13 1.04 0.96 1.13 1.04 0.96 1.13 1.04 0.96 1.13 **Common Antipsychotic Provider (Ref: Pediatrician)** 2.19 0.87 5.50 Others 2.17 0.86 5.45 2.16 0.86 5.44 2.16 0.86 5.43 2.18 0.87 5.48 1.99 0.79 5.05 **Psychiatrist** 1.97 0.78 4.98 1.95 0.77 4.94 1.95 0.77 4.94 1.99 0.79 5.04

General Practice/ Family Practice	1.48	0.47	4.73	1.49	0.47	4.75	1.49	0.47	4.74	1.48	0.47	4.72	1.49	0.47	4.74
Psychologist	0.93	0.27	3.24	0.93	0.27	3.23	0.93	0.27	3.23	0.93	0.27	3.25	0.94	0.27	3.26
Missing	1.46	0.57	3.79	1.46	0.56	3.77	1.46	0.56	3.78	1.46	0.56	3.78	1.46	0.56	3.78
Any Psychiatric related hospita	lization														
Yes	0.85	0.55	1.30	0.85	0.55	1.30	0.85	0.55	1.30	0.84	0.55	1.29	0.84	0.55	1.29
Mental Health (Ref: No)															
Psychotic disorder	1.29	0.67	2.47	1.28	0.67	2.46	1.28	0.67	2.45	1.30	0.68	2.50	1.30	0.68	2.50
ADHD medications or Disruptive behavior disorder	0.89	0.53	1.50	0.89	0.53	1.50	0.89	0.53	1.50	0.90	0.53	1.51	0.90	0.54	1.51
Antidepressants or Mood disorder	1.22	0.73	2.06	1.21	0.72	2.05	1.22	0.72	2.05	1.23	0.73	2.07	1.22	0.72	2.06
Antianxiety or Sedative/hypnotics	1.27	0.62	2.59	1.28	0.63	2.60	1.28	0.63	2.61	1.26	0.62	2.56	1.25	0.62	2.55
Other mental disorder (including tic disorder)	0.83	0.48	1.42	0.82	0.47	1.41	0.82	0.48	1.41	0.83	0.48	1.43	0.83	0.48	1.43
Pervasive developmental disorder	1.16	0.59	2.28	1.15	0.59	2.24	1.15	0.59	2.24	1.18	0.60	2.30	1.18	0.61	2.31
Mood stabilizers	1.08	0.68	1.72	1.07	0.67	1.70	1.07	0.67	1.71	1.08	0.68	1.73	1.08	0.68	1.72
No. of different categories of ps	sychotropic	c medica	tions tak	en (Ref: 0)											
1	0.79	0.52	1.22	0.79	0.52	1.22	0.79	0.52	1.21	0.80	0.52	1.22	0.80	0.52	1.23
>=2	0.79	0.42	1.49	0.80	0.42	1.50	0.79	0.42	1.49	0.80	0.43	1.51	0.81	0.43	1.52
No. of different categories of ps	ychiatric o	disorders	diagnos	sed (Ref: 0)											
1	1.28	0.74	2.21	1.28	0.74	2.21	1.28	0.74	2.21	1.27	0.73	2.21	1.27	0.73	2.21

Monotherapy vs Polypharmacy	0.9	9414		0.4	274		0.	6167		C	0.5820				
Intragroup Comparison#	Pr>	ChiSq		Pr>	ChiSq		Pr>	ChiSq		Pr	> ChiSq				
>=2	3.11	1.13	8.57	3.05	1.11	8.42	3.06	1.11	8.42	3.19	1.16	8.77	3.18	1.15	8.77
1	1.36	0.85	2.16	1.36	0.86	2.17	1.36	0.86	2.18	1.35	0.85	2.15	1.35	0.85	2.15
Charlson comorbidity score	(Ref• (1)														
>=4	1.55	0.29	8.15	1.57	0.30	8.27	1.57	0.30	8.28	1.51	0.29	7.97	1.51	0.29	7.93
3	1.63	0.52	5.05	1.64	0.53	5.08	1.63	0.53	5.07	1.62	0.52	5.03	1.62	0.52	5.03
2	1.08	0.48	2.39	1.08	0.49	2.41	1.08	0.49	2.41	1.07	0.48	2.38	1.07	0.48	2.39

AHR=Adjusted Hazard Ratio

^{*} For the liberal definition, time before polypharmacy initiation was considered as monotherapy time and time afterwards was considered as polypharmacy time;

@- For this analysis, monotherapy was used as the reference group. #- Wald test for equal coefficients

Table S4: Cox Regression Model for Metabolic adverse events Using Time Varying Dose (No Use, Low Dose, High Dose) Definition and lag dose effect and sensitivity analysis by excluding patients with less than 14 days of overlap days Sensitivity analysis by excluding patients with <14 overlap All patients days No lag dose effect Lag dose effect No lag dose effect Lag dose effect Parameter AHR 95% CI AHR 95% CI **AHR** 95% CI **AHR** 95% CI Low Low Low Low High High High High Dose (Ref: No dose) Low dose 0.87 1.09 1.56 0.73 1.21 1.69 0.76 1.20 0.85 1.69 1.05 1.51 High dose 2.42 1.35 4.32 2.17 1.34 3.53 2.33 1.25 4.34 2.09 1.26 3.47 Age group (Ref: 16-17 vears) 1-6 years 0.39 0.17 0.89 0.38 0.17 0.88 0.43 0.19 0.99 0.43 0.19 0.99 0.94 0.93 7-12 years 0.62 0.41 0.61 0.40 0.67 0.44 1.04 0.67 0.43 1.03 13-15 years 1.06 0.73 1.53 1.06 0.74 1.53 1.12 0.77 1.64 1.13 0.77 1.65 Gender (Ref: Male) Female 1.12 0.82 1.55 1.12 0.82 1.54 1.15 0.83 1.59 1.15 0.83 1.59 Region (Ref: Mid-west) East 1.27 0.87 1.85 1.27 0.87 1.85 1.18 0.80 1.76 1.19 0.80 1.76 South 1.32 1.35 0.87 0.57 1.33 0.87 0.57 0.89 0.58 1.36 0.88 0.58 West 0.95 0.54 0.31 0.95 0.54 0.30 0.51 0.28 0.92 0.51 0.28 0.92 0.97 1.14 0.97 1.14 1.04 0.96 1.04 0.96 Index year 1.05 1.05 1.13 1.13 Common Antipsychotic Provider (Ref: Pediatrician) 0.81 0.81 2.12 0.84 2.11 0.84 5.31 Others 1.16 1.66 1.16 1.66 5.34 1.91 0.75 Psychiatrist 0.61 0.26 1.44 0.62 0.26 1.45 1.92 4.87 4.84 0.76 General Practice/ Family 0.86 0.41 1.82 0.86 0.41 1.82 1.47 0.46 4.69 1.45 0.46 4.63 Practice Psychologist 0.47 0.19 1.17 0.47 0.19 1.17 0.92 0.27 3.22 0.92 0.26 3.21 Missing 0.70 1.12 0.44 1.12 0.55 3.71 0.44 0.70 1.44 0.56 3.74 1.43

Any Psychiatric related hos	spitalization	n										
Yes	0.87	0.57	1.31	0.86	0.57	1.30	0.84	0.55	1.29	0.84	0.54	1.28
Mental Health (Ref: No)												
Psychotic disorder	1.30	0.69	2.44	1.29	0.69	2.42	1.29	0.66	2.42	1.25	0.65	2.40
ADHD medications or	0.93	0.57	1.54	0.94	0.57	1.55	0.89	0.53	1.50	0.90	0.54	1.51
Disruptive behavior												
disorder												
Antidepressants or Mood	1.18	0.71	1.95	1.18	0.71	1.96	1.22	0.72	2.05	1.23	0.73	2.07
disorder												
Antianxiety or	1.25	0.63	2.46	1.24	0.63	2.45	1.25	0.61	2.54	1.24	0.61	2.52
Sedative/hypnotics												
Other mental disorder	0.90	0.54	1.52	0.91	0.54	1.53	0.81	0.47	1.40	0.82	0.48	1.41
(including tic disorder)												
Pervasive developmental	1.15	0.60	2.23	1.16	0.60	2.25	1.17	0.60	2.28	1.18	0.61	2.31
disorder												
Mood stabilizers	0.98	0.63	1.54	0.98	0.62	1.53	1.04	0.65	1.66	1.03	0.65	1.64
No. of different categories of	of nevelotr	onic med	ications to	ken (Ref•	U)							
		_	1.35			1.36	0.80	0.52	1.22	0.81	0.53	1 24
	0.89	0.58	1.33	0.90	0.59 0.51	1.36		0.52	1.23		0.53	1.24
>=2	0.93	0.50	1./3	0.94	0.51	1./4	0.80	0.43	1.51	0.81	0.43	1.53
No. of different categories of	of psychiatı	ric disord	lers diagn	osed (Ref:	0)							
1	1.18	0.70	2.01	1.19	0.70	2.01	1.29	0.74	2.24	1.29	0.74	2.24
2	1.00	0.47	2.14	1.00	0.47	2.13	1.09	0.49	2.42	1.08	0.49	2.41
3	1.34	0.45	3.95	1.33	0.45	3.91	1.65	0.53	5.13	1.64	0.53	5.06
>=4	1.09	0.22	5.43	1.09	0.22	5.42	1.54	0.29	8.11	1.53	0.29	8.06
Charlson comorbidity score	e (Ref· 0)											
	1.36	0.86	2.14	1.36	0.86	2.15	1.37	0.86	2.18	1.37	0.86	2.19
>=2	2.88	1.05	7.92	2.89	1.05	7.97	3.21	1.17	8.83	3.25	1.18	8.95
Intragroup comparison of Dose#	Pr >	> ChiSq		Pr >	ChiSq		Pr > C	hiSq		Pr	> ChiSq	l
Low dose vs High dose	0.	.0197		0.0	030		0.03	56		(0.0049	

#- Wald test for equal coefficients

Table S5: Cox regression model								
Monotherapy-High dose, Polyph	armacy-Any dose) and	sensitivi All patie	•	by excluding	Sensitivity analy		•	_
		•			<1	4 overla		
Parameter	Adjusted Hazard		6 CI	Pr > ChiSq	Adjusted		6 CI	Pr > ChiS
	Ratio	Low	High		Hazard Ratio	Low	High	\mathbf{q}
Exposure-dose (Ref: No use)								
Monotherapy-low dose	1.20	0.86	1.68	0.2791	1.203	0.853	1.695	0.2920
Monotherapy-high dose	2.34	1.26	4.36	0.0073	2.177	1.111	4.267	0.0234
Polypharmacy-any dose	2.34	0.85	6.46	0.1009	2.036	0.635	6.533	0.2319
Age group (Ref: 16-17 years)								
1-6 years	0.39	0.17	0.89	0.0251	0.429	0.186	0.991	0.0477
7-12 years	0.62	0.41	0.94	0.0250	0.675	0.437	1.043	0.0769
13-15 years	1.06	0.73	1.53	0.7572	1.123	0.767	1.642	0.5512
Gender (Ref: Male)								
Female	1.12	0.82	1.54	0.4767	1.146	0.826	1.59	0.4141
Region (Ref: Mid-west)								
East	1.27	0.87	1.85	0.2195	1.183	0.797	1.757	0.4036
South	0.87	0.57	1.33	0.5272	0.891	0.582	1.362	0.5932
West	0.54	0.31	0.96	0.0342	0.514	0.285	0.926	0.0267
Index year	1.05	0.97	1.14	0.2252	1.043	0.961	1.131	0.3131
Common Antipsychotic Provider	(Ref: Pediatrician)							

Others	1.90	0.81	4.42	0.1385	2.128	0.846	5.354	0.1085
Psychiatrist	1.63	0.69	3.83	0.2622	1.92	0.758	4.864	0.1691
General Practice/ Family Practice	1.41	0.48	4.12	0.5283	1.472	0.462	4.693	0.5132
Psychologist	0.76	0.23	2.51	0.6536	0.924	0.265	3.22	0.9008
Missing	1.15	0.48	2.77	0.7571	1.444	0.558	3.738	0.4492
Any Psychiatric related hospitalization								
Yes	0.87	0.57	1.31	0.499	0.843	0.55	1.294	0.4354
Mental Health (Ref: No)								
Psychotic disorder	1.30	0.69	2.43	0.4182	1.259	0.656	2.417	0.4887
ADHD medications or Disruptive behavior disorder	0.93	0.57	1.54	0.7873	0.889	0.529	1.494	0.6572
Antidepressants or Mood disorder	1.17	0.70	1.94	0.5478	1.213	0.719	2.047	0.4685
Antianxiety or Sedative/hypnotics	1.25	0.64	2.47	0.5148	1.254	0.615	2.557	0.5334
Other mental disorder (including tic disorder)	0.90	0.53	1.52	0.6893	0.813	0.471	1.401	0.4553
Pervasive developmental disorder	1.15	0.60	2.22	0.6782	1.164	0.596	2.273	0.6565
Mood stabilizers	0.98	0.62	1.54	0.9297	1.042	0.654	1.66	0.8634
No. of different categories of psychotropi	c medications t	aken (Ref	: 0)					
1	0.89	0.58	1.35	0.5737	0.8	0.521	1.229	0.3083
>=2	0.94	0.51	1.73	0.8332	0.804	0.427	1.513	0.4985
No. of different categories of psychiatric	disorders diagr	nosed (Ref	: 0)					
1	1.18	0.70	2.01	0.5349	1.286	0.741	2.232	0.3709
2	1.01	0.47	2.15	0.9838	1.092	0.492	2.426	0.8288
3	1.34	0.46	3.96	0.5915	1.657	0.534	5.139	0.3819

>=4	1.10	0.22	5.46	0.9102	1.55	0.294	8.165	0.6051
Charlson comorbidity score (Ref: 0)								
1	1.36	0.86	2.15	0.1862	1.367	0.857	2.182	0.1891
>=2	2.81	1.02	7.75	0.0458	3.138	1.138	8.65	0.0271
Intragroup comparison of Exposure-dose#		Pr > ChiS	q			Pr > Chi	Sq	
Monotherapy-Low dose vs Monotherapy-high dose		0.0347				0.0825	í	
Monotherapy-Low dose vs Polypharmacy-any dose		0.1970				0.3741		
Monotherapy-high dose vs Polypharmacy-any dose		0.9986				0.9195	i	
#- Wald test for equal coefficients								

		All Patient	ts		Sensitivity analysi	s by exclu		ients with
Parameter	Adjusted Hazard	95%	CI	Pr > ChiSq	<14 Adjusted	95%		Pr > Chi
	Ratio	Low	High	1	Hazard Ratio	Low	High	Sq
Type of antipsychotic (Ref: N	No							
use) FGA (alone or with SGA)	0.89	0.12	6.45	0.9038	0.99	0.14	7.26	0.9929
SGA only	1.33	0.96	1.83	0.0852	1.30	0.93	1.81	0.1234
Age group (Ref: 16-17 years))							
1-6 years	0.39	0.17	0.90	0.0265	0.43	0.19	1.00	0.0491
7-12 years	0.63	0.42	0.96	0.0332	0.69	0.44	1.06	0.0904
13-15 years	1.05	0.73	1.52	0.7960	1.11	0.76	1.63	0.5793
Gender (Ref: Male)								
Female	1.11	0.81	1.53	0.5171	1.14	0.82	1.58	0.4390
Region (Ref: Mid-west)								
East	1.27	0.87	1.85	0.2127	1.19	0.80	1.77	0.3857
South	0.89	0.58	1.35	0.5687	0.91	0.59	1.38	0.6443
West	0.55	0.31	0.97	0.0374	0.52	0.29	0.94	0.0291
Index year	1.05	0.97	1.14	0.2351	1.04	0.96	1.13	0.3159
Common Antipsychotic Prov	vider (Ref: Pediatrician)							
Others	1.94	0.83	4.52	0.1242	2.17	0.86	5.45	0.1005
Psychiatrist	1.68	0.71	3.94	0.2348	1.96	0.77	4.96	0.1561

General Practice/ Family	1.42	0.49	4.15	0.5186	1.49	0.47	4.74	0.5032
Practice Psychologist	0.76	0.23	2.52	0.6590	0.93	0.27	3.22	0.9028
Missing	1.17	0.23	2.32	0.7298	1.46	0.56	3.78	0.4346
Missing	1.17	0.49	2.81	0.7298	1.40	0.56	3.78	0.4340
Any Psychiatric related hospitalization								
Yes	0.87	0.58	1.31	0.5037	0.85	0.55	1.30	0.4405
Mental Health (Ref: No)								
Psychotic disorder	1.32	0.70	2.48	0.3873	1.28	0.67	2.45	0.4604
ADHD medications or Disruptive behavior disorder	0.93	0.56	1.54	0.7773	0.89	0.53	1.50	0.6561
Antidepressants or Mood disorder	1.17	0.71	1.95	0.5402	1.22	0.72	2.05	0.4616
Antianxiety or Sedative/hypnotics	1.29	0.65	2.53	0.4688	1.28	0.63	2.60	0.5006
Other mental disorder (including tic disorder)	0.91	0.54	1.53	0.7198	0.82	0.48	1.42	0.4855
Pervasive developmental disorder	1.13	0.58	2.19	0.7216	1.15	0.59	2.24	0.6911
Mood stabilizers	1.02	0.65	1.60	0.9364	1.07	0.68	1.71	0.7617
No. of different categories of psychotro	pic medications	s taken (Ref:	: 0)					
1	0.87	0.57	1.32	0.5131	0.79	0.51	1.21	0.2758
>=2	0.91	0.49	1.68	0.7622	0.79	0.42	1.48	0.4583
No. of different categories of psychiatri	c disorders dia	gnosed (Ref	: 0)					
1	1.17	0.69	1.98	0.5623	1.28	0.74	2.21	0.3877
2	1.00	0.47	2.13	0.9891	1.08	0.49	2.40	0.8541
3	1.32	0.45	3.90	0.6143	1.63	0.52	5.06	0.3985
>=4	1.12	0.23	5.60	0.8877	1.57	0.30	8.30	0.5927

Charlson comorbidity score (Ref: 0)								
1	1.34	0.85	2.12	0.2031	1.36	0.85	2.17	0.1990
>=2	2.75	1.00	7.57	0.0499	3.09	1.12	8.50	0.0292
Intragroup comparison of type of antipsychotic#	Pr > ChiSq				Pr > ChiSq			
Any FGA vs SGA only	0.6890				0.7904			
#- Wald test for equal coefficients								

Antipsychotic polypharmacy and metabolic events